A Phase II Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma (ProSun Study)

Trial Profile

A Phase II Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma (ProSun Study)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Propranolol (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ProSun Study
  • Most Recent Events

    • 21 Mar 2018 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
    • 21 Mar 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
    • 21 Mar 2018 Planned initiation date changed from 1 Dec 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top